## In the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

## l (currently amended). A compound of general formula (I):

$$\bigcap_{OX_1} \bigcap_{OX_2} \bigcap_{OX_2} \bigcap_{(I)}$$

wherein X<sub>1</sub> is H or COR<sub>1</sub> and X<sub>2</sub> is H or COR<sub>2</sub> but X<sub>1</sub> and X<sub>2</sub> are not both H;

 $R_1$  and  $R_2$  are the same or different and are each  $C_{1-4}$  alkyl substituted with  $R_3$ , or a four to seven-membered ring which is substituted with  $R_8$  and can contain or which contains one or more heteroatoms selected from O,  $S(O)_n$  and  $NR_0$ ;

 $R_4$ ,  $R_5$ , and  $R_6$  are the same or different and are each H or  $C_{14}$  alkyl optionally substituted with  $R_3$ , or  $NR_3R_6$  is a  $C_{4\cdot6}$  heterocycloalkyl ring containing one or more heteroatoms selected from O.  $NR_8$  and  $S(O)_n$ :

each n is 0-2;

R7 is C1.4 alkvl:

R<sub>8</sub> is as defined for R<sub>3</sub> or C<sub>1-4</sub> alkyl substituted with R<sub>3</sub> or halogen;

and

Ro is H or C1-4 alkyl;

or a salt, solvate or hydrate thereof.

2 (previously presented). The compound of claim 1, wherein X<sub>1</sub> is COR<sub>1</sub> and X<sub>2</sub> is COR<sub>2</sub>.

- 3 (previously presented). The compound of claim 1, wherein X1 is H and X2 is COR2.
- 4 (previously presented). The compound of claim 1, wherein X1 is COR1 and X2 is H.
- 5 (previously presented). The compound of claim 1, wherein R<sub>3</sub> is CF<sub>3</sub>, OR<sub>4</sub>, NR<sub>5</sub>R<sub>6</sub> or S(O)<sub>0</sub>R<sub>7</sub>.
- 6 (previously presented). The compound of claim 1, which is 4,5-Bis(tetrahydropyran-4-carbonyloxy)-9,10-dioxo-dihydroanthracene-2-carboxylic acid.
  - 7 (withdrawn). The compound of claim 1, which is;
  - 4,5-bisbutyryloxy-9, 10-dioxo-9,10-dihydroanthracene-2-carboxylic acid;
  - 4,5-bis(2-benzyloxyacetyloxy)-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid;
  - 4,5-bis(4-methoxybutyryloxy)-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; or
- 4,5-bis(tetrahydrofuran-3-carbonyloxy)-9, 10-dioxo-9,10-dihydroanthracene-2-carboxylic acid.

8 (currently amended). A pharmaceutical composition for use in therapy, comprising a pharmaceutically acceptable diluent or carrier and a compound of general formula (I):

wherein X1 is H or COR1 and X2 is H or COR2 but X1 and X2 are not both H;

4

 $R_1$  and  $R_2$  are the same or different and are each  $C_{1-4}$  alkyl substituted with  $R_3$ , or a four to seven-membered ring which can be optionally substituted with  $R_8$  and can contain one or more additional heteroatoms selected from O,  $S(O)_n$  and  $NR_9$ ;

R<sub>3</sub> is F, CF<sub>3</sub>, OR<sub>4</sub>, NR<sub>5</sub>R<sub>6</sub> or S(O)<sub>n</sub>R<sub>7</sub>;

 $R_4$ ,  $R_5$ , and  $R_6$  are the same or different and are each H or  $C_{14}$  alkyl optionally substituted with  $R_3$ , or  $NR_5R_6$  is a  $C_{4-6}$  heterocycloalkyl ring containing one or more heteroatoms selected from O,  $NR_5$  and  $S(O)_{hi}$ :

each n is 0-2;

R7 is C1-4 alkyl;

R<sub>8</sub> is as defined for R<sub>3</sub> or C<sub>1-4</sub> alkyl optionally substituted with R<sub>3</sub> or halogen;

and

Ro is H or C14 alkyl;

or a salt, solvate or hydrate thereof.

9 - 24 (cancelled).